Main > ONCOLOGY (**) > Endometrial Cancer > TREAT.: > JP. E. Lenvatinib+PembrolizuMAb

---

JP. E. Lenvatinib+PembrolizuMAb's subsections
(*) AU Approval Date: 2019. 09.17.
(*) CA Approval Date: 2019. 09.17.
(*) JP Approval Date: 2021. 12.27
(*) USA Approval Date: 2019. 09.17.
Advanced Endometrial Carcinoma
Companies
Disease Progression>Prior Systemic
Not MSI-H or dMMR
TradeMark
TradeMark Web-Site

JP. E. Lenvatinib+PembrolizuMAb's products
This section has no products